Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Research organization ChemDiv has entered into a discovery research collaboration with Berlex, a US affiliate of Schering AG. The partners will work on the discovery of potential new lead compounds against several selected G-protein coupled receptor targets.
Subscribe to our email newsletter
A large number of therapeutic drugs currently on the market involve G-protein coupled receptors (GPCR) in their mechanisms of action. However there is still great potential for further development in this area.
Under the terms of the collaboration, ChemDiv will apply its integrated synthetic and medicinal chemistry capabilities and collaborate with Berlex’s scientists in the search for new disease therapies. Financial terms were not disclosed.
“We are looking forward to the opportunity to work with Berlex and view this as further validation of our discovery chemistry expertise. ChemDiv’s integrated drug discovery capabilities provide an excellent fit for Berlex and we hope that our collaborative relationship will be a long-standing one,” said Alexander Kiselyov, executive VP of R&D at ChemDiv.